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A 53 year old woman was referred to us because of large goiter, enlarged pituitary and grossly elevated TSH and
free T4. The differential diagnosis included a TSH producing adenoma vs. artifactual laboratory tests. A careful
step-by step analysis of different possibilities allowed correct diagnosis and treatment.In this Clinical Case Seminar, a real patient’s information
(in bold font) and an expert clinician’s comments
(in regular font) are presented for the reader. The authors’
comments are in the Background and Summary.Background
The constellation of a goiter, enlarged pituitary and
grossly elevated TSH and free T4 suggest a TSH produ-
cing adenoma. However, when the patient also has high
titers of thyroglobulin and thyroid peroxidase antibodies,
artifactual laboratory tests should also be considered in
the differential diagnosis.Case presentation
The patient is a 53 year old woman who was evaluated
for a large goiter but was otherwise well. Laboratory
evaluation revealed a markedly elevated TSH of 82
(Normal: 0.55-4.78 mIU/L) and extremely elevated
levels of thyroglobulin antibodies (246,617; Normal: 0–
40 IU/mL) and thyroid peroxidase antibodies (47,097;
Normal: 0–35 IU/mL) She recalled having a goiter
since at least her teenage years, indicating the condi-
tion is long standing, perhaps even congenital or gen-
etic. Over the past several years the size of the goiter
had increased to a degree that was cosmetically
troublesome and did not allow her to button her col-
lars (Fig. 1). On the other hand, growth and develop-
ment were normal and she presented in a clinically
euthyroid state, implying that the clinical conse-
quences of the disorder have been minimal. The family* Correspondence: abarkan@umich.edu
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mother, but was otherwise unremarkable.
The constellation of goiter, extremely high TSH and
grossly elevated thyroid antibodies strongly suggest the
diagnosis of Hashimoto’s thyroiditis with primary
hypothyroidism. Surprisingly, she had no symptoms or
signs of clinical hypothyroidism.
Unexpectedly, she was found to have markedly ele-
vated level of Free T4 at 5.5 (Normal: 0.8-1.8 ng/dL),
and a laboratory error was excluded by repeat values
of TSH 125 mIU/L and FT4 5.2 ng/dL.
The referring physician considered a TSH-secreting
pituitary tumor or thyroid hormone resistance as po-
tential diagnoses, and ordered additional tests. This
further workup revealed mildly elevated alpha sub-
unit of pituitary glycoprotein hormones (2.1; Normal:
0–1.4 ng/mL), and low Free T3 (2.0; Normal: 2.3-
4.2 pg/mL). Thyroid ultrasound demonstrated
diffusely-enlarged gland without any nodules and I-
123 imaging revealed an enlarged thyroid that lacked
dominant masses or distinct hot or cold nodules. Pi-
tuitary MRI revealed a diffusely enlarged gland with
a minor degree of suprasellar expansion but no ag-
gressive features. The gland was isointense on T1
without contrast and diffusely and homogenously hy-
perintense on T1 with gadolinium contrast (Fig. 2).
The patient was referred to our clinic.
On physical examination she appeared to be well
and had no symptoms or signs of hypothyroidism
or thyrotoxicosis. She had a large, easily visible
goiter of at least 80 ml in volume. Neck circumfer-
ence was 15 inches. Other than that she had no
pathological findings. She was not taking any medi-
cations with the exception of occasional NSAIDs or
multivitamins.is article is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
um, provided you give appropriate credit to the original author(s) and the
ons license, and indicate if changes were made. The Creative Commons
eativecommons.org/publicdomain/zero/1.0/) applies to the data made
ted.
Fig. 1 Photograph of the patient’s neck with large goiter
easily visible
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vated FT4 in the presence of an enlarged pituitary and dif-
fuse goiter is focused on either a pituitary TSH-producing
tumor or on thyroid hormone resistance.
The lack of any signs or symptoms of hyperthyroidism
despite the FT4 of 5.2 ng/dl argues against a TSH-secreting
tumor, since in that case we would expect the markedly ele-
vated FT4 to have clinical consequences. Furthermore, the
FT3 would be expected to be elevated roughly in propor-
tion to the FT4, yet in this patient the FT3 was low. The
pituitary alpha glycoprotein subunit was elevated, as
would be expected with a TSH-secreting adenoma.Fig. 2 Pituitary MRI study. Left: T1 without contrast, Right: T1 with
gadolinium contrast. Pituitary gland is symmetrically enlarged and
enhances homogenously with gadolinium contrastHowever, this 53 year old woman was post-menopausal
and the elevated alpha subunit could easily be
accounted for by the appropriately-elevated LH and
FSH. Diffuse pituitary enlargement with characteristic
pattern of contrast enhancement could simply reflect
pituitary hyperplasia due to the trophic effects of long-
standing TRH stimulation, consistent with her long
history of goiter and presumed longstanding elevated
TSH [1].
Similarly, the diagnosis of thyroid hormone resistance
is not fully consistent with this case. Thyroid hormone
resistance is a congenital condition, often but not always
inherited in an autosomal dominant pattern [2]. Most
cases are due to mutations in thyroid hormone receptor
beta that decrease the affinity of the receptor for T3.
The history of goiter at a young age is consistent with
this diagnosis, as is the more-or-less clinically euthyroid
state and the presence of elevated TSH and FT4. How-
ever, in thyroid hormone resistance, the TSH is only
mildly elevated or sometimes in the upper half of the
reference range, which still is inappropriate in the con-
text of an elevated FT4. Another major difficulty invok-
ing the diagnosis of thyroid hormone resistance is the
fact that this patient has a low FT3. In thyroid hormone
resistance, the FT3 should be elevated roughly in pro-
portion to the FT4 (similar to TSH-secreting adenoma).
In fact, the most striking aspect of the laboratory
evaluation is the discordance between the FT4 (elevated)
and FT3 (low). Since T4 is the precursor to T3, it is diffi-
cult to square these findings. One might postulate that
the low FT3 is in fact the fundamental problem, lead-
ing to the elevated TSH, which then leads to the ele-
vated FT4 in an attempt to compensate. The clinically
euthyroid state might be consistent with the only
slightly low FT3 as well as perhaps contributions of the
elevated FT4 to thyroid hormone action, either by dir-
ect binding of T4 to T3 receptors or by local conver-
sion to T3 by the type 2 deiodinase. But how could the
T3 be selectively low? Perhaps there is excessive activ-
ity of a T3-degrading enzyme. The problem with this
hypothesis is that T3 and T4 are degraded by the same
enzyme (type 3 deiodinase) [3]. One might postulate a
mutant type 3 deiodinase that avidly degrades T3 in
preference to T4, but there is no precedent for any
such change in enzyme specificity.
How about, then, a defect in the conversion of T4 to
T3? Amiodarone can block T4 to T3 conversion. Amio-
darone administration results in a transient elevation of
TSH, but the level rarely exceeds 15 mIU/L and is ex-
pected to return to the reference range within a few
months of initiation of therapy [4]. Amiodarone causes a
chronic elevation in FT4 without an elevation in FT3,
but the FT4 is only slightly elevated. And of course this
patient was not taking amiodarone. Still, the response to
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has a mutation of the deiodinase that converts T4 to T3.
There actually are two such enzymes, the types 1 and 2
deiodinases [5]. The type 1 deiodinase is primarily
expressed in the liver and is thought to account for a
substantial fraction of the circulating T3. The type 2
deiodinase is expressed in the brain, pituitary, brown
fat and a few other locations, and is thought to provide
local T3 that may or may not contribute substantially
to the T3 in the circulation. A major problem invoking
the diagnosis of deiodinase mutation is that no such
cases have ever been described.
All three deiodinases are selenoproteins, unusual en-
zymes that contain the amino acid selenocysteine in the
catalytic site. The human genome encodes approximately
two dozen selenoproteins, and the synthesis of these
proteins requires a series a highly specialized enzymes. Sev-
eral patients have been described who have a mutation in
one of those proteins, selenocysteine binding protein 2
(SECIS binding protein 2, SBP2). These patients have a gen-
eralized defect in the ability to produce selenoproteins, al-
though not all selenoproteins are equally affected. Subjects
with SBP2 mutations have elevated FT4 and low FT3, but
the TSH is normal or just slightly elevated, and the thyroid
is not enlarged [6]. Thus, our patient does not fit the pic-
ture seen with SBP2 mutations. However, only a few cases
have been reported, so it is possible that the laboratory
findings may expand if more cases are identified.
When a patient is found to have unusual thyroid func-
tion tests, and especially if the clinical presentation and
test results do not fit well with a known syndrome, it is
important to consider the possibility of laboratory
artifact. In our patient, the combination of elevated
TSH, elevated FT4 and low FT3 should raise this possi-
bility. But which of these tests would be subject to
artifact? The elevated TSH seems likely real because it is
consistent with two clinical correlates – goiter and an
enlarged pituitary. Since the mildly low FT3 is consistent
with the elevated TSH, attention turns to the validity of
the FT4 measurement. The commonly used clinical FT4
assays are called “analog” methods because a labeled T4
analog competes with the serum free T4 for binding to
an antibody. These assays occasionally can give spurious
results due to interfering substances in the serum. In
fact, although it is generally agreed that FT4 assays are
more reliably interpreted than the old-fashioned total T4
assay, some have questioned this [7]. One such possibil-
ity is familial dysalbuminemic hyperthyroxinemia. It is
caused by mutations in the albumin gene that increases
the affinity of albumin for T4 by ~60-fold. Some assays
that rely on the competition of a T4 analog with un-
bound T4 in the sample can give falsely-elevated results.
Doing a “two-step” assay, in which T4 analog never
comes in contact with mutant albumin due to a washstep before capture avoids this problem. However, the
Siemens Centaur assay employed in our laboratory per-
forms as well or even better than some of the two-step
assays [8]. Thus, this possibility does not appear to ex-
plain the high free T4 values in this patient. Another
possibility is the so-called HAMA ( human anti-mouse
antibody) phenomenon. It is most often encountered
in people who are chronically exposed to mouse
proteins ( home mouse infestation, vivarium or pet
store workers etc.). The endogenous heterophile human
antibodies against mouse proteins may interfere in the as-
says based on mouse-derived monoclonal antibodies and
give spuriously high results. Therefore, performing an assay
utilizing patient’s plasma treated with a blocking reagent is
indicated in this case.
A HAMA assays for FT4 was performed, but the
measured concentration of the analyte did not
change: 6.2 ng/dL
In situations where the validity of a FT4 assay is in
question, it is sometimes necessary to measure the total
hormone.
In this patient, total T4 was only 3.6 ( Normal: 4.5-
10.9 mcg/dL) with a normal thyroxine binding globulin
of 21 (Normal: 11–27 mcg/mL).
The total T4 concentration is obviously low and fully
compatible with elevated TSH and low T3 concentra-
tions. This strongly suggests that the original suspicion
of Hashimoto’s thyroiditis with primary hypothyroidism
was actually correct despite apparently elevated FT4
levels measured by the analog method. Therefore, the
gold standard of FT4 measurement, i.e. equilibrium dia-
lysis, needs to be performed to clinch the diagnosis.
Free T4 measured by equilibrium dialysis, was <0.5
(Normal: 0.8-2.0 ng/dL). In addition, the reverse T3
was low at 6.8 (Normal: 10–24 ng/dL), which is the
expected result if the true free T4 is low and the pa-
tient is hypothyroid.
Summary
Thus, the overall results are consistent with a diagnosis of
hypothyroidism, with an artifactual elevation in the
originally-measured FT4 due to the presence of an un-
known interfering substance.
It is noteworthy that this patient has very high titers
of thyroglobulin and thyroid peroxidase antibodies,
suggesting a diagnosis of Hashimoto’s thyroiditis. Very
high titers of thyroglobulin antibodies can be associ-
ated with endogenous thyroid hormone antibodies,
since T4 (and T3) molecules are present within mature
thyroglobulin. These thyroid hormone autoantibodies
can be a source of assay interference and can result in
spuriously elevated FT4 measurements in the typical
clinical assays that use analog methods [9]. Thyroid
hormone autoantibodies also would be expected to
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ure free T4 by equilibrium dialysis are much less
susceptible. Although the exact nature of the interfering
substance in this patient is not known, the overall
laboratory picture leads to the diagnosis of hypothyroidism,
and thus informs the clinician of the need to treat with
levothyroxine. In addition, it is clear that standard clinical
FT4 assays should be avoided in evaluating thyroid function
in this patient.
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